Please login to the form below

Not currently logged in
Email:
Password:

Novel muscle relaxant reverser wins US priority review status

The FDA assigns priority review status to US-based pharmaceutical company Schering-Plough's NDA for sugammadex

The FDA has assigned priority review status to US-based pharmaceutical company Schering-Plough's (S-P) New Drug Application (NDA) for sugammadex.

Sugammadex reverses the effects of US-marketed muscle relaxants, such as Zemuron (rocuronium) and vecuronium, which are used in general anaesthesia during surgical procedures.

If approved, sugammadex will be the first in a new class of drugs known as selective relaxant binding agents which encapsulate the muscle relaxant molecule and render it inactive.

S-P's CMO, Dr Robert Spiegel, said: "Sugammadex has the potential to change the way doctors practice anaesthesia as it will allow anaesthesiologists to rapidly and safely reverse both shallow and profound levels of muscle relaxation, which is not possible with current reversal agents."

S-P acquired sugammadex through its acquisition of Organon BioSciences on 19 November 2007.

3rd January 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...

Infographics